nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—RRM2—Hydroxyurea—head and neck cancer	0.283	0.375	CbGbCtD
Cladribine—RRM1—Hydroxyurea—head and neck cancer	0.283	0.375	CbGbCtD
Cladribine—NR5A1—Vinblastine—head and neck cancer	0.151	0.2	CbGbCtD
Cladribine—SLC22A2—Vinblastine—head and neck cancer	0.0154	0.0204	CbGbCtD
Cladribine—ABCG2—Fluorouracil—head and neck cancer	0.0123	0.0163	CbGbCtD
Cladribine—ABCG2—Docetaxel—head and neck cancer	0.00936	0.0124	CbGbCtD
Cladribine—PNP—tongue—head and neck cancer	0.0035	0.0704	CbGeAlD
Cladribine—RRM1—larynx—head and neck cancer	0.00347	0.0699	CbGeAlD
Cladribine—POLE3—hair follicle—head and neck cancer	0.00263	0.0529	CbGeAlD
Cladribine—PNP—mouth—head and neck cancer	0.00235	0.0473	CbGeAlD
Cladribine—PNP—Paclitaxel—Docetaxel—head and neck cancer	0.00172	0.602	CbGdCrCtD
Cladribine—Floxuridine—TYMS—head and neck cancer	0.0016	0.557	CrCbGaD
Cladribine—POLE4—head—head and neck cancer	0.00154	0.0309	CbGeAlD
Cladribine—RRM2B—parotid gland—head and neck cancer	0.00152	0.0306	CbGeAlD
Cladribine—Myelosuppression—Hydroxyurea—head and neck cancer	0.00147	0.015	CcSEcCtD
Cladribine—Lung infiltration—Hydroxyurea—head and neck cancer	0.00147	0.015	CcSEcCtD
Cladribine—RRM2B—saliva-secreting gland—head and neck cancer	0.00146	0.0293	CbGeAlD
Cladribine—POLE3—parotid gland—head and neck cancer	0.00144	0.0289	CbGeAlD
Cladribine—POLE3—saliva-secreting gland—head and neck cancer	0.00138	0.0277	CbGeAlD
Cladribine—RRM1—hair follicle—head and neck cancer	0.00137	0.0276	CbGeAlD
Cladribine—RRM2B—connective tissue—head and neck cancer	0.00134	0.0269	CbGeAlD
Cladribine—RRM2—mouth—head and neck cancer	0.0013	0.0261	CbGeAlD
Cladribine—Trifluridine—TYMS—head and neck cancer	0.00127	0.443	CrCbGaD
Cladribine—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00125	0.0127	CcSEcCtD
Cladribine—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.00115	0.0117	CcSEcCtD
Cladribine—RRM2—Vinorelbine—Vinblastine—head and neck cancer	0.00114	0.398	CbGdCrCtD
Cladribine—Blepharitis—Hydroxyurea—head and neck cancer	0.00112	0.0115	CcSEcCtD
Cladribine—RRM2B—trachea—head and neck cancer	0.00112	0.0226	CbGeAlD
Cladribine—Polyneuropathy—Docetaxel—head and neck cancer	0.0011	0.0112	CcSEcCtD
Cladribine—Ileus—Vinblastine—head and neck cancer	0.00107	0.0109	CcSEcCtD
Cladribine—POLE3—trachea—head and neck cancer	0.00106	0.0214	CbGeAlD
Cladribine—Myelosuppression—Fluorouracil—head and neck cancer	0.00106	0.0108	CcSEcCtD
Cladribine—PNP—lymphoid tissue—head and neck cancer	0.00105	0.0212	CbGeAlD
Cladribine—POLE—saliva-secreting gland—head and neck cancer	0.00105	0.0211	CbGeAlD
Cladribine—Neuritis—Vinblastine—head and neck cancer	0.00102	0.0104	CcSEcCtD
Cladribine—SLC28A3—trachea—head and neck cancer	0.000993	0.02	CbGeAlD
Cladribine—POLA1—parotid gland—head and neck cancer	0.000944	0.019	CbGeAlD
Cladribine—POLE2—lymph node—head and neck cancer	0.00094	0.0189	CbGeAlD
Cladribine—Neurotoxicity—Docetaxel—head and neck cancer	0.000926	0.00945	CcSEcCtD
Cladribine—POLE3—lymphoid tissue—head and neck cancer	0.000924	0.0186	CbGeAlD
Cladribine—NR5A1—lymphoid tissue—head and neck cancer	0.000896	0.018	CbGeAlD
Cladribine—RRM2B—thyroid gland—head and neck cancer	0.000888	0.0179	CbGeAlD
Cladribine—Extravasation—Vinblastine—head and neck cancer	0.000869	0.00886	CcSEcCtD
Cladribine—PNP—head—head and neck cancer	0.000849	0.0171	CbGeAlD
Cladribine—POLE3—thyroid gland—head and neck cancer	0.000839	0.0169	CbGeAlD
Cladribine—Cellulitis—Vinblastine—head and neck cancer	0.000834	0.0085	CcSEcCtD
Cladribine—Febrile neutropenia—Fluorouracil—head and neck cancer	0.000827	0.00843	CcSEcCtD
Cladribine—Pulmonary fibrosis—Docetaxel—head and neck cancer	0.000816	0.00833	CcSEcCtD
Cladribine—POLE—trachea—head and neck cancer	0.00081	0.0163	CbGeAlD
Cladribine—Blepharitis—Fluorouracil—head and neck cancer	0.000809	0.00825	CcSEcCtD
Cladribine—Bone pain—Vinblastine—head and neck cancer	0.000791	0.00807	CcSEcCtD
Cladribine—RRM2B—head—head and neck cancer	0.000788	0.0159	CbGeAlD
Cladribine—Myelosuppression—Docetaxel—head and neck cancer	0.000766	0.00781	CcSEcCtD
Cladribine—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.000745	0.0076	CcSEcCtD
Cladribine—POLE3—head—head and neck cancer	0.000745	0.015	CbGeAlD
Cladribine—NR5A1—head—head and neck cancer	0.000722	0.0145	CbGeAlD
Cladribine—POLE—lymphoid tissue—head and neck cancer	0.000705	0.0142	CbGeAlD
Cladribine—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.000704	0.00718	CcSEcCtD
Cladribine—Lymphopenia—Docetaxel—head and neck cancer	0.000702	0.00716	CcSEcCtD
Cladribine—Neoplasm—Vinblastine—head and neck cancer	0.000685	0.00699	CcSEcCtD
Cladribine—Mucosal inflammation—Docetaxel—head and neck cancer	0.000649	0.00661	CcSEcCtD
Cladribine—POLE—thyroid gland—head and neck cancer	0.00064	0.0129	CbGeAlD
Cladribine—Phlebitis—Vinblastine—head and neck cancer	0.000639	0.00651	CcSEcCtD
Cladribine—Neoplasm—Hydroxyurea—head and neck cancer	0.000625	0.00637	CcSEcCtD
Cladribine—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.000619	0.00631	CcSEcCtD
Cladribine—Febrile neutropenia—Docetaxel—head and neck cancer	0.000597	0.00609	CcSEcCtD
Cladribine—Polyp—Docetaxel—head and neck cancer	0.00059	0.00602	CcSEcCtD
Cladribine—DCK—parotid gland—head and neck cancer	0.000582	0.0117	CbGeAlD
Cladribine—RRM2—lymphoid tissue—head and neck cancer	0.000581	0.0117	CbGeAlD
Cladribine—Extravasation—Fluorouracil—head and neck cancer	0.00057	0.00582	CcSEcCtD
Cladribine—POLE—head—head and neck cancer	0.000568	0.0114	CbGeAlD
Cladribine—Oral candidiasis—Docetaxel—head and neck cancer	0.000565	0.00577	CcSEcCtD
Cladribine—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000561	0.00573	CcSEcCtD
Cladribine—Disorientation—Hydroxyurea—head and neck cancer	0.000561	0.00572	CcSEcCtD
Cladribine—Hepatic failure—Hydroxyurea—head and neck cancer	0.000558	0.00569	CcSEcCtD
Cladribine—DCK—saliva-secreting gland—head and neck cancer	0.000558	0.0112	CbGeAlD
Cladribine—POLA1—thyroid gland—head and neck cancer	0.000552	0.0111	CbGeAlD
Cladribine—RRM2B—lymph node—head and neck cancer	0.000552	0.0111	CbGeAlD
Cladribine—Cellulitis—Fluorouracil—head and neck cancer	0.000547	0.00558	CcSEcCtD
Cladribine—Renal failure acute—Hydroxyurea—head and neck cancer	0.000543	0.00554	CcSEcCtD
Cladribine—Cyst—Docetaxel—head and neck cancer	0.000537	0.00548	CcSEcCtD
Cladribine—Redness—Docetaxel—head and neck cancer	0.000532	0.00543	CcSEcCtD
Cladribine—RRM2—thyroid gland—head and neck cancer	0.000527	0.0106	CbGeAlD
Cladribine—POLE3—lymph node—head and neck cancer	0.000521	0.0105	CbGeAlD
Cladribine—Inflammation—Fluorouracil—head and neck cancer	0.000513	0.00523	CcSEcCtD
Cladribine—Interstitial lung disease—Docetaxel—head and neck cancer	0.000507	0.00517	CcSEcCtD
Cladribine—Ileus—Docetaxel—head and neck cancer	0.000507	0.00517	CcSEcCtD
Cladribine—RRM1—lymphoid tissue—head and neck cancer	0.000482	0.00971	CbGeAlD
Cladribine—Neuritis—Docetaxel—head and neck cancer	0.000481	0.00491	CcSEcCtD
Cladribine—Rash erythematous—Docetaxel—head and neck cancer	0.000469	0.00478	CcSEcCtD
Cladribine—RRM2—head—head and neck cancer	0.000468	0.00942	CbGeAlD
Cladribine—Pancytopenia—Vinblastine—head and neck cancer	0.000452	0.00461	CcSEcCtD
Cladribine—Myocardial ischaemia—Docetaxel—head and neck cancer	0.000447	0.00456	CcSEcCtD
Cladribine—RRM1—thyroid gland—head and neck cancer	0.000438	0.00882	CbGeAlD
Cladribine—Sepsis—Fluorouracil—head and neck cancer	0.000432	0.0044	CcSEcCtD
Cladribine—DCK—trachea—head and neck cancer	0.00043	0.00866	CbGeAlD
Cladribine—Pancytopenia—Hydroxyurea—head and neck cancer	0.000412	0.0042	CcSEcCtD
Cladribine—Extravasation—Docetaxel—head and neck cancer	0.000412	0.0042	CcSEcCtD
Cladribine—Swelling—Fluorouracil—head and neck cancer	0.000409	0.00418	CcSEcCtD
Cladribine—Neutropenia—Hydroxyurea—head and neck cancer	0.000406	0.00414	CcSEcCtD
Cladribine—Disorientation—Fluorouracil—head and neck cancer	0.000404	0.00412	CcSEcCtD
Cladribine—POLE—lymph node—head and neck cancer	0.000398	0.00801	CbGeAlD
Cladribine—Bone disorder—Docetaxel—head and neck cancer	0.000398	0.00405	CcSEcCtD
Cladribine—RRM1—head—head and neck cancer	0.000389	0.00783	CbGeAlD
Cladribine—Infestation NOS—Hydroxyurea—head and neck cancer	0.000387	0.00394	CcSEcCtD
Cladribine—Infestation—Hydroxyurea—head and neck cancer	0.000387	0.00394	CcSEcCtD
Cladribine—Haemoglobin—Vinblastine—head and neck cancer	0.000383	0.0039	CcSEcCtD
Cladribine—Haemorrhage—Vinblastine—head and neck cancer	0.000381	0.00388	CcSEcCtD
Cladribine—Blood bilirubin increased—Docetaxel—head and neck cancer	0.00038	0.00387	CcSEcCtD
Cladribine—Pharyngitis—Vinblastine—head and neck cancer	0.000378	0.00385	CcSEcCtD
Cladribine—Bone pain—Docetaxel—head and neck cancer	0.000375	0.00382	CcSEcCtD
Cladribine—DCK—lymphoid tissue—head and neck cancer	0.000375	0.00754	CbGeAlD
Cladribine—Inflammation—Docetaxel—head and neck cancer	0.00037	0.00378	CcSEcCtD
Cladribine—Cardiac failure—Fluorouracil—head and neck cancer	0.00037	0.00377	CcSEcCtD
Cladribine—Lethargy—Fluorouracil—head and neck cancer	0.000369	0.00376	CcSEcCtD
Cladribine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000366	0.00373	CcSEcCtD
Cladribine—Pulmonary embolism—Docetaxel—head and neck cancer	0.000359	0.00366	CcSEcCtD
Cladribine—Injection site reaction—Docetaxel—head and neck cancer	0.000357	0.00364	CcSEcCtD
Cladribine—Haemoglobin—Hydroxyurea—head and neck cancer	0.000349	0.00356	CcSEcCtD
Cladribine—Haemorrhage—Hydroxyurea—head and neck cancer	0.000347	0.00354	CcSEcCtD
Cladribine—POLA1—lymph node—head and neck cancer	0.000343	0.0069	CbGeAlD
Cladribine—Candida infection—Docetaxel—head and neck cancer	0.000343	0.0035	CcSEcCtD
Cladribine—DCK—thyroid gland—head and neck cancer	0.00034	0.00685	CbGeAlD
Cladribine—Ataxia—Fluorouracil—head and neck cancer	0.00034	0.00346	CcSEcCtD
Cladribine—Alopecia—Vinblastine—head and neck cancer	0.000336	0.00343	CcSEcCtD
Cladribine—RRM2—lymph node—head and neck cancer	0.000328	0.0066	CbGeAlD
Cladribine—ABCG2—parotid gland—head and neck cancer	0.000325	0.00654	CbGeAlD
Cladribine—Neoplasm—Docetaxel—head and neck cancer	0.000325	0.00331	CcSEcCtD
Cladribine—Muscular weakness—Fluorouracil—head and neck cancer	0.000319	0.00325	CcSEcCtD
Cladribine—Angiopathy—Hydroxyurea—head and neck cancer	0.000315	0.00321	CcSEcCtD
Cladribine—Sepsis—Docetaxel—head and neck cancer	0.000312	0.00318	CcSEcCtD
Cladribine—Chills—Hydroxyurea—head and neck cancer	0.000311	0.00318	CcSEcCtD
Cladribine—ABCG2—saliva-secreting gland—head and neck cancer	0.000311	0.00626	CbGeAlD
Cladribine—Eosinophilia—Fluorouracil—head and neck cancer	0.000309	0.00315	CcSEcCtD
Cladribine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000307	0.00314	CcSEcCtD
Cladribine—Alopecia—Hydroxyurea—head and neck cancer	0.000307	0.00313	CcSEcCtD
Cladribine—Anaemia—Vinblastine—head and neck cancer	0.000306	0.00312	CcSEcCtD
Cladribine—Phlebitis—Docetaxel—head and neck cancer	0.000303	0.00309	CcSEcCtD
Cladribine—Erythema—Hydroxyurea—head and neck cancer	0.000302	0.00308	CcSEcCtD
Cladribine—DCK—head—head and neck cancer	0.000302	0.00608	CbGeAlD
Cladribine—Malaise—Vinblastine—head and neck cancer	0.000299	0.00305	CcSEcCtD
Cladribine—Pancytopenia—Fluorouracil—head and neck cancer	0.000296	0.00302	CcSEcCtD
Cladribine—Swelling—Docetaxel—head and neck cancer	0.000295	0.00301	CcSEcCtD
Cladribine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00029	0.00296	CcSEcCtD
Cladribine—Hepatic failure—Docetaxel—head and neck cancer	0.00029	0.00296	CcSEcCtD
Cladribine—DCK—Nucleotide metabolism—GPX1—head and neck cancer	0.000289	0.00312	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.000288	0.00311	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—head and neck cancer	0.000285	0.00308	CbGpPWpGaD
Cladribine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00028	0.00286	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.00028	0.00302	CbGpPWpGaD
Cladribine—Pneumonia—Fluorouracil—head and neck cancer	0.00028	0.00285	CcSEcCtD
Cladribine—Anaemia—Hydroxyurea—head and neck cancer	0.000279	0.00285	CcSEcCtD
Cladribine—Discomfort—Vinblastine—head and neck cancer	0.000279	0.00284	CcSEcCtD
Cladribine—Infestation NOS—Fluorouracil—head and neck cancer	0.000278	0.00284	CcSEcCtD
Cladribine—Infestation—Fluorouracil—head and neck cancer	0.000278	0.00284	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—CEBPA—head and neck cancer	0.000276	0.00298	CbGpPWpGaD
Cladribine—Atrial fibrillation—Docetaxel—head and neck cancer	0.000275	0.00281	CcSEcCtD
Cladribine—Renal impairment—Docetaxel—head and neck cancer	0.000274	0.00279	CcSEcCtD
Cladribine—POLE2—G1 to S cell cycle control—CCND1—head and neck cancer	0.000274	0.00296	CbGpPWpGaD
Cladribine—Malaise—Hydroxyurea—head and neck cancer	0.000272	0.00278	CcSEcCtD
Cladribine—RRM1—lymph node—head and neck cancer	0.000272	0.00548	CbGeAlD
Cladribine—Conjunctivitis—Fluorouracil—head and neck cancer	0.000271	0.00276	CcSEcCtD
Cladribine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000271	0.00276	CcSEcCtD
Cladribine—Cardiac failure—Docetaxel—head and neck cancer	0.000267	0.00272	CcSEcCtD
Cladribine—Lethargy—Docetaxel—head and neck cancer	0.000266	0.00271	CcSEcCtD
Cladribine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000265	0.0027	CcSEcCtD
Cladribine—Epistaxis—Fluorouracil—head and neck cancer	0.000263	0.00268	CcSEcCtD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000262	0.00283	CbGpPWpGaD
Cladribine—Pain in extremity—Docetaxel—head and neck cancer	0.000261	0.00266	CcSEcCtD
Cladribine—Anorexia—Vinblastine—head and neck cancer	0.000258	0.00263	CcSEcCtD
Cladribine—SLC22A1—head—head and neck cancer	0.000257	0.00518	CbGeAlD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000255	0.00261	CcSEcCtD
Cladribine—Discomfort—Hydroxyurea—head and neck cancer	0.000254	0.00259	CcSEcCtD
Cladribine—Haemoglobin—Fluorouracil—head and neck cancer	0.000251	0.00256	CcSEcCtD
Cladribine—RRM2—G1/S Transition—TYMS—head and neck cancer	0.00025	0.0027	CbGpPWpGaD
Cladribine—Haemorrhage—Fluorouracil—head and neck cancer	0.00025	0.00255	CcSEcCtD
Cladribine—Pharyngitis—Fluorouracil—head and neck cancer	0.000248	0.00253	CcSEcCtD
Cladribine—Oedema—Hydroxyurea—head and neck cancer	0.000247	0.00252	CcSEcCtD
Cladribine—Ataxia—Docetaxel—head and neck cancer	0.000245	0.0025	CcSEcCtD
Cladribine—Infection—Hydroxyurea—head and neck cancer	0.000245	0.0025	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.000243	0.00263	CbGpPWpGaD
Cladribine—Paraesthesia—Vinblastine—head and neck cancer	0.000243	0.00248	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—PTEN—head and neck cancer	0.000243	0.00262	CbGpPWpGaD
Cladribine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000242	0.00247	CcSEcCtD
Cladribine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000241	0.00246	CcSEcCtD
Cladribine—POLE—G1/S Transition—TYMS—head and neck cancer	0.00024	0.00259	CbGpPWpGaD
Cladribine—Skin disorder—Hydroxyurea—head and neck cancer	0.00024	0.00244	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000239	0.00258	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.000239	0.00258	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—TYMS—head and neck cancer	0.000236	0.00255	CbGpPWpGaD
Cladribine—Anorexia—Hydroxyurea—head and neck cancer	0.000235	0.0024	CcSEcCtD
Cladribine—Decreased appetite—Vinblastine—head and neck cancer	0.000235	0.0024	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000235	0.00239	CcSEcCtD
Cladribine—Pain—Vinblastine—head and neck cancer	0.000231	0.00236	CcSEcCtD
Cladribine—Constipation—Vinblastine—head and neck cancer	0.000231	0.00236	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—RARB—head and neck cancer	0.000228	0.00246	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000225	0.00243	CbGpPWpGaD
Cladribine—Arrhythmia—Fluorouracil—head and neck cancer	0.000223	0.00228	CcSEcCtD
Cladribine—Feeling abnormal—Vinblastine—head and neck cancer	0.000223	0.00227	CcSEcCtD
Cladribine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000221	0.00226	CcSEcCtD
Cladribine—Alopecia—Fluorouracil—head and neck cancer	0.000221	0.00225	CcSEcCtD
Cladribine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00022	0.00224	CcSEcCtD
Cladribine—Somnolence—Hydroxyurea—head and neck cancer	0.000219	0.00224	CcSEcCtD
Cladribine—Erythema—Fluorouracil—head and neck cancer	0.000218	0.00222	CcSEcCtD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000216	0.00233	CbGpPWpGaD
Cladribine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000214	0.00219	CcSEcCtD
Cladribine—Pancytopenia—Docetaxel—head and neck cancer	0.000214	0.00218	CcSEcCtD
Cladribine—Abdominal pain—Vinblastine—head and neck cancer	0.000214	0.00218	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCNA1—head and neck cancer	0.000213	0.0023	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000213	0.00217	CcSEcCtD
Cladribine—Fatigue—Hydroxyurea—head and neck cancer	0.000213	0.00217	CcSEcCtD
Cladribine—DCK—lymph node—head and neck cancer	0.000211	0.00426	CbGeAlD
Cladribine—RRM2—Mitotic G1-G1/S phases—TYMS—head and neck cancer	0.000211	0.00228	CbGpPWpGaD
Cladribine—Pain—Hydroxyurea—head and neck cancer	0.000211	0.00215	CcSEcCtD
Cladribine—Constipation—Hydroxyurea—head and neck cancer	0.000211	0.00215	CcSEcCtD
Cladribine—Neutropenia—Docetaxel—head and neck cancer	0.000211	0.00215	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—YAP1—head and neck cancer	0.000208	0.00224	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.000205	0.00221	CbGpPWpGaD
Cladribine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000203	0.00207	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—TYMS—head and neck cancer	0.000202	0.00219	CbGpPWpGaD
Cladribine—Pneumonia—Docetaxel—head and neck cancer	0.000202	0.00206	CcSEcCtD
Cladribine—Anaemia—Fluorouracil—head and neck cancer	0.000201	0.00205	CcSEcCtD
Cladribine—Infestation—Docetaxel—head and neck cancer	0.000201	0.00205	CcSEcCtD
Cladribine—Infestation NOS—Docetaxel—head and neck cancer	0.000201	0.00205	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	0.0002	0.00216	CbGpPWpGaD
Cladribine—Hypersensitivity—Vinblastine—head and neck cancer	0.000199	0.00203	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000199	0.00203	CcSEcCtD
Cladribine—Renal failure—Docetaxel—head and neck cancer	0.000197	0.00201	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—EGFR—head and neck cancer	0.000197	0.00213	CbGpPWpGaD
Cladribine—Conjunctivitis—Docetaxel—head and neck cancer	0.000195	0.00199	CcSEcCtD
Cladribine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000195	0.00199	CcSEcCtD
Cladribine—Asthenia—Vinblastine—head and neck cancer	0.000194	0.00198	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000194	0.00209	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00019	0.00194	CcSEcCtD
Cladribine—ABCG2—thyroid gland—head and neck cancer	0.00019	0.00382	CbGeAlD
Cladribine—Epistaxis—Docetaxel—head and neck cancer	0.000189	0.00193	CcSEcCtD
Cladribine—Chest pain—Fluorouracil—head and neck cancer	0.000185	0.00189	CcSEcCtD
Cladribine—Myalgia—Fluorouracil—head and neck cancer	0.000185	0.00189	CcSEcCtD
Cladribine—Diarrhoea—Vinblastine—head and neck cancer	0.000185	0.00189	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000183	0.00198	CbGpPWpGaD
Cladribine—Discomfort—Fluorouracil—head and neck cancer	0.000183	0.00187	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	0.000182	0.00196	CbGpPWpGaD
Cladribine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000182	0.00185	CcSEcCtD
Cladribine—Haemoglobin—Docetaxel—head and neck cancer	0.000181	0.00185	CcSEcCtD
Cladribine—POLE2—G1 to S cell cycle control—TP53—head and neck cancer	0.00018	0.00195	CbGpPWpGaD
Cladribine—Haemorrhage—Docetaxel—head and neck cancer	0.00018	0.00184	CcSEcCtD
Cladribine—Confusional state—Fluorouracil—head and neck cancer	0.000179	0.00183	CcSEcCtD
Cladribine—Pharyngitis—Docetaxel—head and neck cancer	0.000179	0.00183	CcSEcCtD
Cladribine—Dizziness—Vinblastine—head and neck cancer	0.000179	0.00182	CcSEcCtD
Cladribine—Urinary tract disorder—Docetaxel—head and neck cancer	0.000178	0.00182	CcSEcCtD
Cladribine—Oedema peripheral—Docetaxel—head and neck cancer	0.000178	0.00181	CcSEcCtD
Cladribine—Oedema—Fluorouracil—head and neck cancer	0.000178	0.00181	CcSEcCtD
Cladribine—Connective tissue disorder—Docetaxel—head and neck cancer	0.000177	0.00181	CcSEcCtD
Cladribine—Asthenia—Hydroxyurea—head and neck cancer	0.000177	0.0018	CcSEcCtD
Cladribine—Urethral disorder—Docetaxel—head and neck cancer	0.000177	0.0018	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—CCND1—head and neck cancer	0.000176	0.0019	CbGpPWpGaD
Cladribine—Infection—Fluorouracil—head and neck cancer	0.000176	0.0018	CcSEcCtD
Cladribine—Nervous system disorder—Fluorouracil—head and neck cancer	0.000174	0.00178	CcSEcCtD
Cladribine—RRM1—Metabolism—UROD—head and neck cancer	0.000174	0.00188	CbGpPWpGaD
Cladribine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000174	0.00177	CcSEcCtD
Cladribine—Tachycardia—Fluorouracil—head and neck cancer	0.000173	0.00177	CcSEcCtD
Cladribine—Vomiting—Vinblastine—head and neck cancer	0.000172	0.00175	CcSEcCtD
Cladribine—POLE2—Cell Cycle—RAD51—head and neck cancer	0.000172	0.00185	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—TYMS—head and neck cancer	0.000171	0.00185	CbGpPWpGaD
Cladribine—Erythema multiforme—Docetaxel—head and neck cancer	0.000171	0.00174	CcSEcCtD
Cladribine—POLE2—S Phase—CCND1—head and neck cancer	0.00017	0.00184	CbGpPWpGaD
Cladribine—Headache—Vinblastine—head and neck cancer	0.000169	0.00173	CcSEcCtD
Cladribine—Anorexia—Fluorouracil—head and neck cancer	0.000169	0.00173	CcSEcCtD
Cladribine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000169	0.00172	CcSEcCtD
Cladribine—Eye disorder—Docetaxel—head and neck cancer	0.000169	0.00172	CcSEcCtD
Cladribine—Cardiac disorder—Docetaxel—head and neck cancer	0.000167	0.00171	CcSEcCtD
Cladribine—Hypotension—Fluorouracil—head and neck cancer	0.000166	0.00169	CcSEcCtD
Cladribine—RRM2B—Direct p53 effectors—TP53—head and neck cancer	0.000166	0.00179	CbGpPWpGaD
Cladribine—Angiopathy—Docetaxel—head and neck cancer	0.000164	0.00167	CcSEcCtD
Cladribine—Dizziness—Hydroxyurea—head and neck cancer	0.000163	0.00166	CcSEcCtD
Cladribine—Immune system disorder—Docetaxel—head and neck cancer	0.000163	0.00166	CcSEcCtD
Cladribine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000163	0.00166	CcSEcCtD
Cladribine—Chills—Docetaxel—head and neck cancer	0.000162	0.00165	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000162	0.00165	CcSEcCtD
Cladribine—Arrhythmia—Docetaxel—head and neck cancer	0.000161	0.00164	CcSEcCtD
Cladribine—Nausea—Vinblastine—head and neck cancer	0.000161	0.00164	CcSEcCtD
Cladribine—Insomnia—Fluorouracil—head and neck cancer	0.000161	0.00164	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.00016	0.00173	CbGpPWpGaD
Cladribine—Paraesthesia—Fluorouracil—head and neck cancer	0.000159	0.00163	CcSEcCtD
Cladribine—Alopecia—Docetaxel—head and neck cancer	0.000159	0.00163	CcSEcCtD
Cladribine—Dyspnoea—Fluorouracil—head and neck cancer	0.000158	0.00161	CcSEcCtD
Cladribine—POLE2—Mitotic G1-G1/S phases—CCND1—head and neck cancer	0.000158	0.00171	CbGpPWpGaD
Cladribine—Mental disorder—Docetaxel—head and neck cancer	0.000158	0.00161	CcSEcCtD
Cladribine—Somnolence—Fluorouracil—head and neck cancer	0.000158	0.00161	CcSEcCtD
Cladribine—Erythema—Docetaxel—head and neck cancer	0.000157	0.0016	CcSEcCtD
Cladribine—Malnutrition—Docetaxel—head and neck cancer	0.000157	0.0016	CcSEcCtD
Cladribine—Vomiting—Hydroxyurea—head and neck cancer	0.000157	0.0016	CcSEcCtD
Cladribine—Rash—Hydroxyurea—head and neck cancer	0.000155	0.00159	CcSEcCtD
Cladribine—Dermatitis—Hydroxyurea—head and neck cancer	0.000155	0.00158	CcSEcCtD
Cladribine—Headache—Hydroxyurea—head and neck cancer	0.000154	0.00158	CcSEcCtD
Cladribine—Decreased appetite—Fluorouracil—head and neck cancer	0.000154	0.00157	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.000154	0.00166	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000153	0.00156	CcSEcCtD
Cladribine—Back pain—Docetaxel—head and neck cancer	0.000152	0.00155	CcSEcCtD
Cladribine—Pain—Fluorouracil—head and neck cancer	0.000152	0.00155	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000151	0.00163	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000148	0.0016	CbGpPWpGaD
Cladribine—Nausea—Hydroxyurea—head and neck cancer	0.000146	0.00149	CcSEcCtD
Cladribine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000146	0.00149	CcSEcCtD
Cladribine—Anaemia—Docetaxel—head and neck cancer	0.000145	0.00148	CcSEcCtD
Cladribine—RRM2B—Metabolism—NAT2—head and neck cancer	0.000145	0.00157	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000145	0.00156	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—TYMS—head and neck cancer	0.000144	0.00156	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCNA1—head and neck cancer	0.000143	0.00155	CbGpPWpGaD
Cladribine—RRM2—Metabolism—UROD—head and neck cancer	0.000143	0.00155	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000141	0.00152	CbGpPWpGaD
Cladribine—Urticaria—Fluorouracil—head and neck cancer	0.000141	0.00144	CcSEcCtD
Cladribine—Body temperature increased—Fluorouracil—head and neck cancer	0.00014	0.00143	CcSEcCtD
Cladribine—POLE—Cell Cycle—CCNA1—head and neck cancer	0.000138	0.00149	CbGpPWpGaD
Cladribine—Cough—Docetaxel—head and neck cancer	0.000137	0.0014	CcSEcCtD
Cladribine—DCK—Metabolism—UROD—head and neck cancer	0.000134	0.00144	CbGpPWpGaD
Cladribine—Arthralgia—Docetaxel—head and neck cancer	0.000134	0.00136	CcSEcCtD
Cladribine—Chest pain—Docetaxel—head and neck cancer	0.000134	0.00136	CcSEcCtD
Cladribine—Myalgia—Docetaxel—head and neck cancer	0.000134	0.00136	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000133	0.00135	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000133	0.00143	CbGpPWpGaD
Cladribine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000131	0.00133	CcSEcCtD
Cladribine—Confusional state—Docetaxel—head and neck cancer	0.000129	0.00132	CcSEcCtD
Cladribine—Oedema—Docetaxel—head and neck cancer	0.000128	0.00131	CcSEcCtD
Cladribine—Infection—Docetaxel—head and neck cancer	0.000127	0.0013	CcSEcCtD
Cladribine—RRM2B—Metabolism—DPYD—head and neck cancer	0.000127	0.00137	CbGpPWpGaD
Cladribine—PNP—Metabolism—NAT2—head and neck cancer	0.000126	0.00136	CbGpPWpGaD
Cladribine—Nervous system disorder—Docetaxel—head and neck cancer	0.000126	0.00128	CcSEcCtD
Cladribine—Pruritus—Fluorouracil—head and neck cancer	0.000126	0.00128	CcSEcCtD
Cladribine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000125	0.00128	CcSEcCtD
Cladribine—Tachycardia—Docetaxel—head and neck cancer	0.000125	0.00128	CcSEcCtD
Cladribine—Skin disorder—Docetaxel—head and neck cancer	0.000124	0.00127	CcSEcCtD
Cladribine—Anorexia—Docetaxel—head and neck cancer	0.000122	0.00125	CcSEcCtD
Cladribine—Diarrhoea—Fluorouracil—head and neck cancer	0.000121	0.00124	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000121	0.0013	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—YAP1—head and neck cancer	0.000121	0.0013	CbGpPWpGaD
Cladribine—Hypotension—Docetaxel—head and neck cancer	0.00012	0.00122	CcSEcCtD
Cladribine—ABCG2—lymph node—head and neck cancer	0.000118	0.00237	CbGeAlD
Cladribine—Dizziness—Fluorouracil—head and neck cancer	0.000117	0.0012	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000117	0.00119	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—head and neck cancer	0.000116	0.00125	CbGpPWpGaD
Cladribine—Insomnia—Docetaxel—head and neck cancer	0.000116	0.00118	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—TYMS—head and neck cancer	0.000115	0.00124	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—RAD51—head and neck cancer	0.000115	0.00124	CbGpPWpGaD
Cladribine—Paraesthesia—Docetaxel—head and neck cancer	0.000115	0.00117	CcSEcCtD
Cladribine—Dyspnoea—Docetaxel—head and neck cancer	0.000114	0.00116	CcSEcCtD
Cladribine—Somnolence—Docetaxel—head and neck cancer	0.000114	0.00116	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000114	0.00123	CbGpPWpGaD
Cladribine—Vomiting—Fluorouracil—head and neck cancer	0.000113	0.00115	CcSEcCtD
Cladribine—Rash—Fluorouracil—head and neck cancer	0.000112	0.00114	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—head and neck cancer	0.000112	0.00114	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—head and neck cancer	0.000111	0.00114	CcSEcCtD
Cladribine—Headache—Fluorouracil—head and neck cancer	0.000111	0.00113	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000111	0.00113	CcSEcCtD
Cladribine—POLE—Cell Cycle—RAD51—head and neck cancer	0.000111	0.00119	CbGpPWpGaD
Cladribine—Fatigue—Docetaxel—head and neck cancer	0.00011	0.00113	CcSEcCtD
Cladribine—PNP—Metabolism—DPYD—head and neck cancer	0.00011	0.00119	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—RARB—head and neck cancer	0.00011	0.00119	CbGpPWpGaD
Cladribine—POLE—S Phase—CCND1—head and neck cancer	0.00011	0.00119	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.00011	0.00118	CbGpPWpGaD
Cladribine—Pain—Docetaxel—head and neck cancer	0.00011	0.00112	CcSEcCtD
Cladribine—Constipation—Docetaxel—head and neck cancer	0.00011	0.00112	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000109	0.00118	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000108	0.00117	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—CCND1—head and neck cancer	0.000106	0.00115	CbGpPWpGaD
Cladribine—Feeling abnormal—Docetaxel—head and neck cancer	0.000106	0.00108	CcSEcCtD
Cladribine—Nausea—Fluorouracil—head and neck cancer	0.000105	0.00108	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000105	0.00107	CcSEcCtD
Cladribine—PNP—Metabolism—YAP1—head and neck cancer	0.000105	0.00113	CbGpPWpGaD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—head and neck cancer	0.000104	0.00113	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000103	0.00111	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TYMS—head and neck cancer	0.000103	0.00111	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—CCND1—head and neck cancer	0.000102	0.0011	CbGpPWpGaD
Cladribine—Body temperature increased—Docetaxel—head and neck cancer	0.000101	0.00103	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—head and neck cancer	0.000101	0.00103	CcSEcCtD
Cladribine—NR5A1—Gene Expression—YAP1—head and neck cancer	0.0001	0.00108	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	9.94e-05	0.00107	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCNA1—head and neck cancer	9.8e-05	0.00106	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	9.77e-05	0.00105	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	9.54e-05	0.00103	CbGpPWpGaD
Cladribine—Hypersensitivity—Docetaxel—head and neck cancer	9.44e-05	0.000963	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	9.43e-05	0.00102	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—NOTCH1—head and neck cancer	9.36e-05	0.00101	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	9.29e-05	0.001	CbGpPWpGaD
Cladribine—Asthenia—Docetaxel—head and neck cancer	9.19e-05	0.000937	CcSEcCtD
Cladribine—Pruritus—Docetaxel—head and neck cancer	9.06e-05	0.000924	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—NOTCH1—head and neck cancer	8.81e-05	0.000951	CbGpPWpGaD
Cladribine—Diarrhoea—Docetaxel—head and neck cancer	8.77e-05	0.000894	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	8.52e-05	0.000919	CbGpPWpGaD
Cladribine—Dizziness—Docetaxel—head and neck cancer	8.47e-05	0.000864	CcSEcCtD
Cladribine—Vomiting—Docetaxel—head and neck cancer	8.15e-05	0.000831	CcSEcCtD
Cladribine—Rash—Docetaxel—head and neck cancer	8.08e-05	0.000824	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—head and neck cancer	8.07e-05	0.000872	CbGpPWpGaD
Cladribine—Dermatitis—Docetaxel—head and neck cancer	8.07e-05	0.000823	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	8.06e-05	0.00087	CbGpPWpGaD
Cladribine—Headache—Docetaxel—head and neck cancer	8.03e-05	0.000819	CcSEcCtD
Cladribine—POLA1—Cell Cycle—RAD51—head and neck cancer	7.88e-05	0.00085	CbGpPWpGaD
Cladribine—POLA1—S Phase—CCND1—head and neck cancer	7.82e-05	0.000845	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—TYMS—head and neck cancer	7.73e-05	0.000835	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	7.67e-05	0.000827	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	7.66e-05	0.000827	CbGpPWpGaD
Cladribine—Nausea—Docetaxel—head and neck cancer	7.61e-05	0.000776	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	7.47e-05	0.000806	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—TYMS—head and neck cancer	7.42e-05	0.000801	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—CCND1—head and neck cancer	7.26e-05	0.000784	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—TYMS—head and neck cancer	7.25e-05	0.000782	CbGpPWpGaD
Cladribine—RRM1—Metabolism—NAT2—head and neck cancer	7.22e-05	0.000779	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GSTM1—head and neck cancer	7.16e-05	0.000773	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TYMS—head and neck cancer	6.92e-05	0.000747	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GPX1—head and neck cancer	6.86e-05	0.00074	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	6.8e-05	0.000734	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CYP1A1—head and neck cancer	6.79e-05	0.000733	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	6.65e-05	0.000718	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TYMS—head and neck cancer	6.64e-05	0.000717	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	6.44e-05	0.000695	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	6.41e-05	0.000692	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—MAPK3—head and neck cancer	6.4e-05	0.00069	CbGpPWpGaD
Cladribine—RRM1—Metabolism—DPYD—head and neck cancer	6.33e-05	0.000684	CbGpPWpGaD
Cladribine—PNP—Metabolism—TYMS—head and neck cancer	6.28e-05	0.000678	CbGpPWpGaD
Cladribine—PNP—Metabolism—GSTM1—head and neck cancer	6.21e-05	0.00067	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	6.14e-05	0.000662	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.09e-05	0.000657	CbGpPWpGaD
Cladribine—POLE2—Mitotic M-M/G1 phases—MAPK1—head and neck cancer	6.09e-05	0.000657	CbGpPWpGaD
Cladribine—RRM1—Metabolism—YAP1—head and neck cancer	6.01e-05	0.000649	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	6.01e-05	0.000648	CbGpPWpGaD
Cladribine—RRM2—Metabolism—NAT2—head and neck cancer	5.95e-05	0.000642	CbGpPWpGaD
Cladribine—PNP—Metabolism—GPX1—head and neck cancer	5.95e-05	0.000642	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	5.94e-05	0.000642	CbGpPWpGaD
Cladribine—PNP—Metabolism—CYP1A1—head and neck cancer	5.89e-05	0.000635	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—head and neck cancer	5.8e-05	0.000626	CbGpPWpGaD
Cladribine—DCK—Metabolism—NAT2—head and neck cancer	5.56e-05	0.0006	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	5.54e-05	0.000598	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	5.5e-05	0.000594	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	5.43e-05	0.000587	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—UROD—head and neck cancer	5.36e-05	0.000578	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.31e-05	0.000573	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—UROD—head and neck cancer	5.3e-05	0.000572	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TYMS—head and neck cancer	5.29e-05	0.000571	CbGpPWpGaD
Cladribine—RRM2—Metabolism—DPYD—head and neck cancer	5.21e-05	0.000563	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CCND1—head and neck cancer	5.19e-05	0.00056	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—VEGFA—head and neck cancer	5.15e-05	0.000556	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—head and neck cancer	5.1e-05	0.000551	CbGpPWpGaD
Cladribine—RRM2—Metabolism—YAP1—head and neck cancer	4.95e-05	0.000534	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—UROD—head and neck cancer	4.94e-05	0.000533	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK3—head and neck cancer	4.87e-05	0.000526	CbGpPWpGaD
Cladribine—DCK—Metabolism—DPYD—head and neck cancer	4.87e-05	0.000526	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	4.8e-05	0.000518	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK3—head and neck cancer	4.78e-05	0.000516	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TYMS—head and neck cancer	4.73e-05	0.000511	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MAPK1—head and neck cancer	4.64e-05	0.000501	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—head and neck cancer	4.64e-05	0.000501	CbGpPWpGaD
Cladribine—DCK—Metabolism—YAP1—head and neck cancer	4.62e-05	0.000499	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MAPK1—head and neck cancer	4.55e-05	0.000491	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.54e-05	0.00049	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—NOTCH1—head and neck cancer	4.51e-05	0.000486	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.32e-05	0.000466	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.32e-05	0.000466	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK3—head and neck cancer	4.28e-05	0.000462	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK3—head and neck cancer	4.12e-05	0.000445	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—MAPK1—head and neck cancer	4.07e-05	0.000439	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—head and neck cancer	4.04e-05	0.000436	CbGpPWpGaD
Cladribine—POLE—Mitotic M-M/G1 phases—MAPK1—head and neck cancer	3.92e-05	0.000423	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	3.92e-05	0.000423	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—head and neck cancer	3.89e-05	0.00042	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.75e-05	0.000404	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—head and neck cancer	3.74e-05	0.000404	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—head and neck cancer	3.72e-05	0.000402	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.62e-05	0.000391	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TYMS—head and neck cancer	3.61e-05	0.000389	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTM1—head and neck cancer	3.57e-05	0.000385	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTEN—head and neck cancer	3.52e-05	0.00038	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—head and neck cancer	3.5e-05	0.000378	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—head and neck cancer	3.48e-05	0.000376	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—head and neck cancer	3.42e-05	0.000369	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GPX1—head and neck cancer	3.42e-05	0.000369	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP1A1—head and neck cancer	3.38e-05	0.000365	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—head and neck cancer	3.34e-05	0.000361	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—AKT1—head and neck cancer	3.29e-05	0.000355	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK3—head and neck cancer	3.21e-05	0.000347	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK3—head and neck cancer	3.08e-05	0.000333	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.06e-05	0.00033	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MAPK1—head and neck cancer	3.06e-05	0.00033	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—head and neck cancer	3.05e-05	0.00033	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—head and neck cancer	2.97e-05	0.000321	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK3—head and neck cancer	2.94e-05	0.000317	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTM1—head and neck cancer	2.94e-05	0.000317	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MAPK1—head and neck cancer	2.93e-05	0.000317	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK3—head and neck cancer	2.87e-05	0.00031	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GPX1—head and neck cancer	2.81e-05	0.000304	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK1—head and neck cancer	2.79e-05	0.000302	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP1A1—head and neck cancer	2.78e-05	0.000301	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—head and neck cancer	2.78e-05	0.0003	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK3—head and neck cancer	2.76e-05	0.000298	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTM1—head and neck cancer	2.74e-05	0.000296	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK1—head and neck cancer	2.73e-05	0.000295	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—head and neck cancer	2.66e-05	0.000288	CbGpPWpGaD
Cladribine—DCK—Metabolism—GPX1—head and neck cancer	2.63e-05	0.000284	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK1—head and neck cancer	2.62e-05	0.000283	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP1A1—head and neck cancer	2.6e-05	0.000281	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MAPK3—head and neck cancer	2.49e-05	0.000269	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—head and neck cancer	2.48e-05	0.000268	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—head and neck cancer	2.38e-05	0.000257	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—head and neck cancer	2.29e-05	0.000248	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MAPK1—head and neck cancer	2.25e-05	0.000243	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NAT2—head and neck cancer	2.22e-05	0.00024	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—head and neck cancer	2.2e-05	0.000238	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NAT2—head and neck cancer	2.2e-05	0.000238	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK3—head and neck cancer	2.2e-05	0.000237	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—head and neck cancer	2.15e-05	0.000232	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MAPK1—head and neck cancer	2.1e-05	0.000227	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK1—head and neck cancer	2.09e-05	0.000226	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NAT2—head and neck cancer	2.05e-05	0.000221	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—head and neck cancer	2.03e-05	0.000219	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—head and neck cancer	2.01e-05	0.000217	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK3—head and neck cancer	1.96e-05	0.000212	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—DPYD—head and neck cancer	1.95e-05	0.00021	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—DPYD—head and neck cancer	1.93e-05	0.000208	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK1—head and neck cancer	1.87e-05	0.000202	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—YAP1—head and neck cancer	1.85e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—YAP1—head and neck cancer	1.83e-05	0.000198	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—head and neck cancer	1.81e-05	0.000195	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—DPYD—head and neck cancer	1.8e-05	0.000194	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—head and neck cancer	1.76e-05	0.00019	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—head and neck cancer	1.75e-05	0.000189	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MAPK1—head and neck cancer	1.73e-05	0.000186	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—YAP1—head and neck cancer	1.71e-05	0.000184	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—head and neck cancer	1.69e-05	0.000182	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—head and neck cancer	1.68e-05	0.000182	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—head and neck cancer	1.66e-05	0.000179	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MAPK1—head and neck cancer	1.61e-05	0.000174	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—head and neck cancer	1.57e-05	0.000169	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—head and neck cancer	1.55e-05	0.000167	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—head and neck cancer	1.44e-05	0.000156	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—head and neck cancer	1.39e-05	0.00015	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—head and neck cancer	1.35e-05	0.000146	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—head and neck cancer	1.29e-05	0.000139	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—head and neck cancer	1.24e-05	0.000134	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—head and neck cancer	1.11e-05	0.00012	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—head and neck cancer	1.1e-05	0.000119	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTM1—head and neck cancer	1.1e-05	0.000119	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTM1—head and neck cancer	1.09e-05	0.000117	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GPX1—head and neck cancer	1.05e-05	0.000114	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1A1—head and neck cancer	1.04e-05	0.000112	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GPX1—head and neck cancer	1.04e-05	0.000112	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1A1—head and neck cancer	1.03e-05	0.000111	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—head and neck cancer	1.02e-05	0.000111	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—head and neck cancer	1.02e-05	0.00011	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM1—head and neck cancer	1.01e-05	0.000109	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—head and neck cancer	1.01e-05	0.000109	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GPX1—head and neck cancer	9.7e-06	0.000105	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1A1—head and neck cancer	9.6e-06	0.000104	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—head and neck cancer	9.52e-06	0.000103	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—head and neck cancer	8.32e-06	8.98e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—head and neck cancer	7.78e-06	8.39e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—head and neck cancer	6.19e-06	6.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—head and neck cancer	6.13e-06	6.61e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—head and neck cancer	5.71e-06	6.17e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—head and neck cancer	5.4e-06	5.83e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—head and neck cancer	5.34e-06	5.77e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—head and neck cancer	4.98e-06	5.38e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—head and neck cancer	3.81e-06	4.11e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—head and neck cancer	3.77e-06	4.07e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—head and neck cancer	3.51e-06	3.79e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—head and neck cancer	3.11e-06	3.36e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—head and neck cancer	3.08e-06	3.32e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—head and neck cancer	2.87e-06	3.1e-05	CbGpPWpGaD
